Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
31.58
-0.50 (-1.56%)
May 12, 2026, 4:08 PM HKT
Market Cap4.37B
Revenue (ttm)102.38K -95.8%
Net Income-145.79M
EPS-1.24
Shares Out136.22M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume64,000
Average Volume102,535
Open32.50
Previous Close32.08
Day's Range31.36 - 32.50
52-Week Range13.48 - 32.94
Beta0.84
RSI58.10
Earnings DateMar 27, 2026

About HKG:3378

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases. The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways. The company was incorporated in 2014 and is headquartered in Wuhan, China. [Read more]

Founded 2014
Employees 55
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3378
Full Company Profile

Financial Performance

In 2025, HKG:3378's revenue was 92,000, a decrease of -95.82% compared to the previous year's 2.20 million. Losses were -131.01 million, 13.1% more than in 2024.

Financial numbers in CNY Financial Statements